For example, the phase I trial (NCT03608631) sponsored by the M.D. Anderson Cancer (Texas, USA) investigates the use of mesenchymal stem cells‐derived exosomes for the treatment of stage IV pancreatic cancer patients with the presence of KrasG12D mutation where patients are injected with KrasG12D‐specific siRNA‐loaded exosomes targeting the oncogenic KRAS gene thereby reducing its expression in pancreatic tumours (Kamerkar et al., 2017). The gene discussed is KRAS; the disease is pancreatic neoplasm.